Top 15 Pharmaceuticals Companies in India
In this article, we will take a look at the top 15 pharmaceutical companies in India. For more companies, clickTop 5 Pharmaceutical Companies in India. India is the largest producer of generic medica...
- Supported exchanges /
- NSE /
- LUPIN.NSE
Lupin Limited (LUPIN NSE) stock market data APIs
INR2107.05
71.05(3.5%)
as of November 26, 2024
Price chart is built with Anychart
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
Lupin Limited Financial Data Overview
| 2036 | |
| 2107.05 | |
| - | |
| 2113.15 | |
| 2030.15 | |
| 1194.9113-2312 | |
| 961 278 M | |
| 36.7227 | |
| 456 M | |
| 214 313 M | |
| 18.64 | |
| 0.0039 | |
| 0.585 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'LUPIN',
Type:
'Common Stock',
Name:
'Lupin Limited',
Exchange:
'NSE',
CurrencyCode:
'INR',
CurrencyName:
'Indian Rupee',
CurrencySymbol:
'INR',
CountryName:
'India',
CountryISO:
'IN',
OpenFigi:
NULL,
ISIN:
'INE326A01037',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'March',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
}
Lupin Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 214 313 M
- EBITDA 45 994 M
- Earnings Per Share 57.38
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Lupin Limited Earnings via APIs
- Latest Release 2024-11-07
- EPS/Forecast 16.25
Get Lupin Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Lupin Limited latest news via APIs
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
Lupin Ltd Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables...
- CENTRAL NERVOUS SYSTEM
- LIMITED ACCESS
- LUPIN
- LUPIN LIMITED
- MYOTONIA SYMPTOMS
- MYOTONIC DISORDERS
- NDM
- NEUROMUSCULAR DISORDERS
- SPAIN
- SPANISH MINISTRY OF HEALTH
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
